SuperworthenGene Therapeutics shares outstanding ENGN
Diluted shares outstanding, averaged over each quarter, from 2023.
- Latest quarter, to Jul 31, 2026
- 69.7M
- On a year earlier
- +36.5%
- more shares
enGene Therapeutics had 69.7M diluted shares outstanding on average in Q3 FY26, the quarter to Jul 31, 2026.
That is 36.5% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 51.4M | +16% |
| FY2024 | 44.4M | +6163% |
| FY2023 | 708.7K | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q3 FY26 | 69.7M | +36% | |
| Q2 FY26 | 69.7M | +37% | |
| Q1 FY26 | 67.3M | +32% | |
| Q4 FY25 | 51.4M | +16% | |
| Q3 FY25 | 51.1M | +16% | |
| Q2 FY25 | 51M | +29% | |
| Q1 FY25 | 51M | +120% | |
| Q4 FY24 | 44.4M | +6163% | |
| Q3 FY24 | 44.2M | +6198% | |
| Q2 FY24 | 39.4M | +5579% | |
| Q1 FY24 | 23.2M | +3463% | |
| Q4 FY23 | 708.7K | n/a |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on enGene Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.